This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Oncolytics Biotech
Information provided by (Responsible Party):
Canadian Cancer Trials Group
ClinicalTrials.gov Identifier:
NCT01622543
First received: June 12, 2012
Last updated: March 10, 2017
Last verified: March 2017
June 12, 2012
March 10, 2017
June 11, 2012
July 2017   (Final data collection date for primary outcome measure)
Progression free survival [ Time Frame: 19 months ]
Effect of reolysin in combination with standard FOLFOX6 chemotherapy on the progression free survival of patients with advanced or metastatic colorectal cancer.
Same as current
Complete list of historical versions of study NCT01622543 on ClinicalTrials.gov Archive Site
  • Changes in CEA levels [ Time Frame: Baseline and at 19 months ]
    To investigate additional potential measures of efficacy.
  • Objective response rate [ Time Frame: 19 months ]
    To investigate additional potential measures of efficacy
  • Overall survival [ Time Frame: 19 months ]
    The effect of both treatments on overall survival
  • Molecular response [ Time Frame: 19 months ]
    Potential molecular factors predictive of response by assessment of archival tumour tissue (and serial blood samples)
  • Quality of Life [ Time Frame: 19 months ]
    To explore the Quality of Life (as measured by the EORTC QLQC30).
  • Tolerability and toxicity in patients [ Time Frame: 19 months ]
    Determine the effect of reolysin and Folfox6/bevacizumab in patients.
  • Changes in CEA levels [ Time Frame: Baseline and at 19 months ]
    To investigate additional potential measures of efficacy.
  • Objective response rate [ Time Frame: 19 months ]
    To investigate additional potential measures of efficacy
  • Overall survival [ Time Frame: 19 months ]
    The effect of both treatments on overall survival
  • Molecular response [ Time Frame: 19 months ]
    Potential molecular factors predictive of response by assessment of archival tumour tissue (including KRAS status)
  • Quality of Life [ Time Frame: 19 months ]
    To explore the Quality of Life (as measured by the EORTC QLQC30).
Not Provided
Not Provided
 
Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer
A Randomized Phase II Study of Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Patients With Metastatic Colorectal Cancer.
The purpose of this study is to find out if giving reolysin in combination with FOLFOX6/ bevacizumab can offer better results than standard therapy with FOLFOX6/ bevacizumab.
Researchers doing this study also want to evaluate the side effects of reolysin when given together with FOLFOX6/ bevacizumab.
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Colorectal Cancer
  • Drug: Folfox plus Bevacizumab and reolysin
    FOLFOX6/bevacizumab given every 14 days plus reolysin days 1-5 on cycles 1, 2, 4, 6, 8 and alternate cycles thereafter
  • Drug: Folfox plus Bevacizumab
    FOLFOX6/bevacizumab given every 14 days.
  • Active Comparator: Folfox plus Bevacizumab and Reolysin
    Intervention: Drug: Folfox plus Bevacizumab and reolysin
  • Active Comparator: Folfox plus Bevacizumab
    Intervention: Drug: Folfox plus Bevacizumab
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
109
December 2017
July 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must have a histological diagnosis of colorectal adenocarcinoma.
  • All patients must have a formalin fixed paraffin embedded tissue block (from their primary or metastatic tumour) available for translational studies and must have provided informed consent for the release of the block.
  • Presence of clinically and/or radiologically documented disease. All radiology studies must be performed within 28 days prior to randomization (within 35 days if negative). All patients must have measurable disease as defined by RECIST 1.1.

The criteria for defining measurable disease are as follows:

Chest X-ray ≥ 20 mm CT/MRI scan (with slice thickness of < 5 mm) ≥ 10 mm longest diameter Physical exam (using calipers) ≥ 10 mm Lymph nodes by CT scan ≥ 15 mm measured in short axis

  • Patients must have advanced and or metastatic disease, for which no curative therapy exists and for which systemic therapy is indicated.
  • ECOG performance of 0, 1 or 2.
  • Age ≥ 18 years of age.
  • Previous Therapy

Surgery:

Previous major surgery is permitted provided that it has been at least 21days prior to patient randomization and that wound healing has occurred.

Chemotherapy:

Patients may NOT have received any prior cytotoxic chemotherapy for advanced or metastatic disease. Prior adjuvant fluoropyrimidine-based therapy is permitted provided completed at least one year prior to enrollment and the regimen did not include oxaliplatin or bevacizumab. Exceptions may be made for low dose chemotherapy given as a radiosensitizing agent.

Other Therapy:

Patients may have received other therapies including immunotherapy, or with signal transduction inhibitors, providing that the patient has recovered from all reversible drug related toxicity (with the exception of alopecia) and adequate washout period has been met.

Radiation:

Prior external beam radiation is permitted provided a minimum of 4 weeks has elapsed between the last dose and enrollment to the trial. Exceptions may be made for low dose, non-myelosuppressive radiotherapy after consultation with NCIC CTG.

  • Laboratory Requirements (must be done within 7 days prior to randomization)

Hematology:

Granulocytes (AGC) ≥ 1.5 x 10^9/L Platelets ≥ 100 x 10^9/L

Biochemistry:

Serum creatinine ≤ 1.5 x ULN Total bilirubin ≤ 1.0 x ULN (unless elevated secondary to conditions such as Gilbert's disease) ALT and AST ≤ 3 x ULN (Note: ≤ 5 x ULN if documented liver metastasis) Proteinuria < 2g/24 hrs (screen using spot testing; if ≥ grade 2 repeat with mid-stream urine - if still ≥ grade 2 then urine collection for 24 hours to confirm <2g/24hrs)

  • Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate.

Patients who cannot give informed consent (i.e. mentally incompetent patients, or those physically incapacitated such as comatose patients) are not to be recruited into the study. Patients competent but physically unable to sign the consent form may have the document signed by their nearest relative or legal guardian. Each patient will be provided with a full explanation of the study before consent is requested.

  • Patients must be accessible for treatment and follow-up. Patients registered on this trial must be treated and followed at the participating centre. This implies there must be reasonable geographical limits (for example: 2 hour's driving distance) placed on patients being considered for this trial. Investigators must assure themselves that the patients registered on this trial will be available for complete documentation of the treatment, adverse events, response assessment and follow-up.
  • Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life (EORTC QLQ-C30) in either English or French. The baseline assessment must already have been completed. Inability (illiteracy in English or French, loss of sight, or other equivalent reason) to complete the questionnaires will not make the patient ineligible for the study. However, ability but unwillingness to complete the questionnaires will make the patient ineligible. The baseline assessment must be completed within 14 days prior to randomization.
  • In accordance with NCIC CTG policy, protocol treatment is to begin within 5 working days of patient randomization.

Exclusion Criteria:

  • Patients with a history of other malignancies, except for adequately treated non-melanoma skin cancer or solid tumours curatively treated with no evidence of disease for ≥ 3 years. (Please call NCIC CTG if any questions about the interpretation of this criterion).
  • Patients who are on immunosuppressive therapy or have known HIV infection or active hepatitis B or C.
  • Patients with active or uncontrolled infections or with serious illnesses or medical conditions which would not permit the patient to be managed according to the protocol.
  • Patients with significant cardiac (including uncontrolled hypertension) or pulmonary disease, or active CNS disease or infection.
  • Patients are not eligible if they have a known hypersensitivity to the study drug(s) or their components.
  • Patients with history of central nervous system metastases or untreated spinal cord compression.
  • Patients who have had prior treatment with oxaliplatin or bevacizumab, who have contraindications to treatment with 5FU (for e.g. known DPD deficiency or severe cardiac disease), and or neuropathy > grade 1.
  • Patients who are not sterile unless they use an adequate method of birth control.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT01622543
I210
Yes
Not Provided
Not Provided
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Oncolytics Biotech
Study Chair: Derek Jonker Ottawa Health Research Institute - General Division
Study Chair: Patricia Tang Tom Baker Cancer Centre, Calgary, Canada
Canadian Cancer Trials Group
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP